S&P 500 Down Over 1%; US Retail Sales Top Expectations
Benzinga (Fri, 15-Nov 12:43 PM ET)
Eyenovia plunges as late-stage trial for myopia treatment fails
Seeking Alpha News (Fri, 15-Nov 10:05 AM ET)
Eyenovia Provides Update on Phase 3 CHAPERONE Study
Globe Newswire (Fri, 15-Nov 7:00 AM ET)
Eyenovia’s Promising Growth Prospects: Buy Rating Affirmed by Analyst
TipRanks (Wed, 13-Nov 6:37 AM ET)
Eyenovia’s Strategic Advances and Q3 Financials
TipRanks (Tue, 12-Nov 11:37 PM ET)
Eyenovia GAAP EPS of -$0.11 in-line, revenue of $1.62M beats by $1.51M
Seeking Alpha News (Tue, 12-Nov 4:46 PM ET)
Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Globe Newswire (Tue, 12-Nov 4:05 PM ET)
Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th
Globe Newswire (Thu, 7-Nov 7:00 AM ET)
Globe Newswire (Wed, 23-Oct 7:00 AM ET)
Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device
Globe Newswire (Tue, 1-Oct 7:00 AM ET)
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.
Eyenovia trades on the NASDAQ stock market under the symbol EYEN.
As of November 15, 2024, EYEN stock price declined to $0.11 with 42,354,597 million shares trading.
EYEN has a beta of 1.50, meaning it tends to be more sensitive to market movements. EYEN has a correlation of 0.02 to the broad based SPY ETF.
EYEN has a market cap of $9.42 million. This is considered a Sub-Micro Cap stock.
Last quarter Eyenovia reported $1,625 in Revenue and -$.11 earnings per share. This fell short of revenue expectation by $-158,375 and exceeded earnings estimates by $.02.
In the last 3 years, EYEN traded as high as $5.85 and as low as $.09.
The top ETF exchange traded funds that EYEN belongs to (by Net Assets): VTI, VXF.
EYEN has underperformed the market in the last year with a price return of -91.2% while the SPY ETF gained +32.1%. EYEN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -85.6% and -77.6%, respectively, while the SPY returned +8.0% and +3.0%, respectively.
EYEN support price is $.31 and resistance is $.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EYEN shares will trade within this expected range on the day.